News

100TH U.S. PATIENT TREATED IN IDE CLINICAL TRIALS OF BAGUERA® C CERVICAL DISC PROSTHESIS

LAGUNA HILLS, CA, November 16, 2021 – Spineart USA Inc. announced today that the 100th surgery has been performed in their combined single-level and two-level U.S. Investigational Device Exemption (IDE) Clinical Trials of the BAGUERA® C Cervical Disc Prosthesis. Dr. Armen Khachatryan at The Disc Replacement Center, in Salt Lake City, UT, is currently the leading enroller for the single-level trial, and Dr. Hyun Bae at the Foundation for Spinal Restoration in Santa Monica, CA, is the leading enroller for the two-level trial. The BAGUERA® C implant is an investigational device designed to reconstruct the cervical disc following discectomy for symptomatic cervical disc disease. Download the press release Download the press release

SPINEART SA TODAY ANNOUNCED A PLANNED MANAGEMENT REORGANIZATION

In order to accelerate Spineart's international growth, Jérôme Levieux and Stéphane Mugnier-Jacob, Spineart’s founders and current co-CEOs, have decided to reorganize the company’s leadership team enabling them to focus on highly strategic activities.Effective January 1, 2022, Jérôme Trividic, currently group Chief Strategy Officer and President US, will be named group CEO. Jérôme Levieux and Stéphane Mugnier-Jacob will continue to support actively the team as exclusive senior advisors and Board members. Download the press release Download the press release

SPINEART ANNOUNCES EXECUTIVE APPOINTMENT

Olivier Balouka joins Spineart as Chief Administrative Officer. Spineart is pleased to announce the arrival of Olivier Balouka as Chief Administrative Officer, effective June 1st, 2021. He leads the Finance, Human Resources, Legal and IT departments. Download the press release Download the press release

FIRST U.S. PATIENT TREATED IN SINGLE-LEVEL IDE CLINICAL TRIAL OF BAGUERA® C CERVICAL DISC PROSTHESIS

LAGUNA HILLS, CA, March 2nd, 2021 – Spineart USA Inc. announced today that investigator, Dr. Byron Branch, at Carolina Neurosurgery and Spine Associates in Charlotte NC, performed the first surgery in the single-level U.S. Investigational Device Exemption (IDE) Clinical Trial of the BAGUERA® C Cervical Disc Prosthesis. The BAGUERA® C implant is an investigational device designed to reconstruct the cervical disc following single-level discectomy for symptomatic cervical disc disease. Download the press release Download the press release

FIRST U.S. PATIENT TREATED IN TWO-LEVEL IDE CLINICAL TRIAL OF BAGUERA® C CERVICAL DISC PROSTHESIS

LAGUNA HILLS, CA, February 26, 2021 – Spineart USA Inc. announced today that clinical principal investigator, Dr. Domagoj Coric at Carolina Neurosurgery and Spine Associates and Spine Division Chief at Atrium Musculoskeletal Institute in Charlotte NC, performed the first surgery in the two-level U.S. Investigational Device Exemption (IDE) Clinical Trial of the BAGUERA® C Cervical Disc Prosthesis. The BAGUERA® C implant is an investigational device designed to reconstruct the cervical disc following two-level discectomy at adjacent segments for symptomatic cervical disc disease. Download the press release Download the press release

Spineart reaches definitive agreement to acquire Meditech Spine LLC.

Spineart, a global spine player with headquarters in Geneva, Switzerland and US operations in Laguna Hills, California, has agreed to acquire 100% of Atlanta-based Meditech Spine LLC.Spineart has been a distributor of Meditech Spine’s products in the US since 2019. The companies anticipate significant synergies between the two organizations. As part of the transaction, Meditech Spine’s co-founder and chief executive officer, Eric Flickinger, will join Spineart’s senior management team in the US. Meditech manufactures and markets a portfolio of sterile-packed, barcoded CURE® plates and TALOS® PEEK-HA cages in the US. Spineart manufactures and markets a comprehensive portfolio of sterile-packed, barcoded spinal posterior fixations, 3D-printed Ti-LIFE cages, artificial disc prosthesis and biologics in 50 countries. The transaction is expected to close in July 2020. Download the press release Download the press release